| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mertuzumab | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University | Coronavirus Disease 2019 (COVID-19); Carcinoma, Non-Small-Cell Lung | Details | |
| Meplazumab | HI6H8 | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University | Malaria; Coronavirus Disease 2019 (COVID-19); Malaria, Falciparum | Details |
| Anti-CD147 CAR T cell therapy (Xijing Hospital) | Phase 1 Clinical | Glioblastoma | Details | ||
| CD147-CAR T cell therapy (Peking University People's Hospital) | Phase 1 Clinical | Peking University People'S Hospital | Lymphoma, T-Cell | Details | |
| 89Zr-CD147 | Phase 1 Clinical | Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Iodine[131I] Metuximab | Approved | Chengdu Huasun Biotechnology Co Ltd | Licartin, 利卡汀 | Mainland China | Carcinoma, Hepatocellular | Chengdu Huasun Biotechnology Co Ltd | 2006-10-12 | Carcinoma, Hepatocellular | Details |

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호



